← Patent-cliff monitor small molecule PEMAZYRE PEMIGATINIB
Loss of exclusivity October 2040 latest FDA-listed patent expiry
Company Incyte → See this company's full patent-cliff portfolio Drug detail Brand name PEMAZYRE Active ingredient PEMIGATINIB Strength 9MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2020 Marketing status RX
Listed patents Patent Expires Type 12552792 October 2040 substance, product 11628162 August 2040 use U-3571 11466004 May 2039 use U-3466 9611267 January 2035 substance, product 10131667 April 2034 use U-2809
Regulatory exclusivity Code Expires ODE-404 August 2029 ODE-292 April 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.